The Food and Drug Administration (FDA) has approved a split-dosing regimen for Darzalex (daratumumab; Janssen), which provides clinicians the option of splitting the first infusion of daratumumab over 2 consecutive days.
Advances in genetic and molecular assessment strategies have led to improved outcomes for patients with multiple myeloma.
Each of 3 reduced intensity conditioning regimens yielded similar clinical outcomes in patients with multiple myeloma undergoing allogeneic stem cell transplant.
Though imaging provides a powerful tool for diagnosis and treatment of multiple myeloma, choosing the appropriate technique depends on many factors.
Depth of response corresponded to overall survival and time to next treatment in real-world patients with relapsed/refractory multiple myeloma.
Patients who did not have immune dysregulation had higher overall survival compared with patients who had immune dysregulation.
The investigational antibody construct exploits the power of native effector T cells, supporting antitumor activity shortly after administration.
Stringent CR criteria may not predict clinical outcomes for patients with MM.
Results of a comparison study, presented at ASH 2018, found that salvage HDCT followed by ASCT in patients with relapsed MM did not lead to significant difference in PFS or OS compared with continuous novel agent-based treatment.
Patients who received elotuzumab plus pomalidomide and dexamethasone demonstrated longer progression-free survival.
